Multiple sclerosis drug Tecfidera continues to boost revenue for this biotech–a stalwart of this list, appearing for the seventh time.
News about Biogen
Both Merck and Allergan are reportedly exploring a buyout.
The biotech giant has denied any impropriety.
Companies continued to raise prices significantly in Q1.
Biotech companies are staking big money on the idea that they can relieve pain without addiction.
Better drugs for Alzheimer's and other brain disorders could follow.